X

Trial Profile

A Real-world Study: Efficacy and Safety of Eribulin in the Treatment of Advanced Breast Cancer

Status: Recruiting

Phase of Trial: Phase IV

Latest Information Update: 04 Jan 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Camrelizumab (Primary) ; Eribulin (Primary) ; Pembrolizumab (Primary) ; Pertuzumab (Primary) ; Pyrotinib (Primary) ; Trastuzumab (Primary)
Indications Advanced breast cancer; Triple negative breast cancer
Focus Therapeutic Use

Most Recent Events

06 Jun 2023 Results (n=160) presented at the 59th Annual Meeting of the American Society of Clinical Oncology.
07 Jun 2022 Results (n=47) assessing clinical effectiveness, safety, and treatment pattern of eribulin in first to third-line settings in Chinese advanced breast cancer patients, presented at the 58th Annual Meeting of the American Society of Clinical Oncology.
01 Jan 2021 New trial record

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com